Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–63 of 63 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Opioid Induced Constipation Clear all

Conditions: Opioid-Induced Bowel Dysfunction
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 94
States / cities: Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 79 more

Conditions: Low Back Pain
Interventions: Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 149
States / cities: Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more

Conditions: Bowel Dysfunction, Constipation
Interventions: alvimopan, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 137
States / cities: Birmingham, Alabama • Calera, Alabama • Muscle Shoals, Alabama + 114 more

Conditions: Constipation
Interventions: Tegaserod; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Timeline: 2006 – 2007
U.S. locations: 59
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Opioid-Induced Constipation
Interventions: Methylnaltrexone bromide; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 26
States / cities: Mobile, Alabama • Laguna Hills, California • Lancaster, California + 20 more

Conditions: Opioid-Induced Bowel Dysfunction
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 109
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tempe, Arizona + 93 more

Conditions: Opioid Induced Constipation
Interventions: naloxegol, non-PAMORA; Drug
Lead sponsor: Valinor Pharma LLC; Industry
Eligibility: Not listed
Enrollment: 8,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Wilmington, Delaware • Hines, Illinois

Conditions: Opioid Induced Constipation
Interventions: Polyethylene Glycol 3350, Movantik; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 53
States / cities: Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 46 more

Conditions: Cancer, Bowel Dysfunction
Interventions: alvimopan, placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 14
States / cities: Duarte, California • Fountain Valley, California • La Verne, California + 11 more

Conditions: Opioid-induced Constipation
Interventions: Tegaserod; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Timeline: 2006 – 2007
U.S. locations: 57
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more

Conditions: Opioid-Induced Constipation (OIC)
Interventions: NKTR-118, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 91
States / cities: Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 88 more

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more

Conditions: Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: naloxone hydrochloride; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Constipation
Interventions: N-methylnaltrexone bromide (MOA-728); Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 94
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more

Conditions: Constipation Drug Induced
Interventions: Methylnaltrexone Bromide 150 mg Oral Tablet, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Search by objective public record fields.

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

Naloxegol US PMR CV Safety.

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation